ST. LOUIS — The Missouri Department of Health and Senior Services has approved third vaccine doses of the COVID-19 vaccine for some severely immunocompromised people.
Last week, the Food and Drug Administration ruled that transplant recipients and other similarly immune-compromised patients can get a third dose of either the Pfizer or Moderna vaccine. But the decision offers an extra dose only to those high-risk groups — not the general public.
On Tuesday, the state health department announced it would follow that ruling. DHSS said the following groups quality for a third shot:
- Immunocompromised due to solid organ transplant and taking immune-suppressing medications
- Immunocompromised due to active treatment for solid tumor and hematologic malignancies
- Immune compromised due to Receipt of CAR-T cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate to severe primary immunodeficiency (eg., DiGeorge, Wiskott-Aldrich Syndromes)
- Immunocompromised due to Advanced or untreated HIV infection
- Immunocompromised due to “Active treatment with high-dose corticosteroids or other drugs that may suppress immune response: high dose corticosteroids (ie.,≥ 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blocker or other biologic agents that are immunosuppressive or immunomodulatory”
As early as this week, U.S. health authorities are expected to recommend an extra dose of the vaccine for all Americans eight months after they get their second shot, according to two people who spoke to The Associated Press on condition of anonymity to discuss internal deliberations.
The health department said patients should get a third dose of the same vaccine.
Here are some things to know:
WHY DO SOME PEOPLE NEED AN EXTRA DOSE?
The Pfizer and Moderna vaccines offer powerful protection for otherwise healthy people, but many who take immune-suppressing medications or have diseases that tamp down their immune systems generally get less benefit from the standard two doses. The CDC cited one study suggesting about 40% to 44% of people hospitalized for a so-called breakthrough case — infection after vaccination — are among the immune-compromised.
Those hospitalized patients “did all the right things -- they’re just suffering from a lack of good vaccine protection,” said Dr. Camille Kotton of Massachusetts General Hospital, one of CDC’s advisers.
WHO QUALIFIES FOR EXTRA COVID SHOT?
Roughly 7 million American adults are classified as immune-compromised, but the FDA singled out transplant recipients and others with similar levels of immune suppression. The FDA didn’t spell out exactly who falls into those other categories. But according to the CDC, people with blood cancers, those taking certain cancer chemotherapies, and those taking certain medications such as rituximab for rheumatoid arthritis tend to have especially poor responses to vaccination.
ARE THERE AGE RESTRICTIONS?
For now, the new policy allows a third dose of the Pfizer vaccine for children as young as 12 who also meet the high-risk requirement, but adults only for a third Moderna dose. That's because the Pfizer vaccine currently is the only authorized option for Americans under 18. That could change if Moderna's vaccine eventually is allowed for teens.
WILL I NEED A DOCTOR’S NOTE OR A BLOOD TEST?
The government isn't requiring either — patients will just need to tell the vaccine provider why they're seeking another dose. “We would want to make that as easy as possible,” said Dr. William Schaffner, an infectious diseases expert at Vanderbilt University.
WHAT WILL A THIRD DOSE COST?
Shots given under FDA’s emergency use authorization are free.
IS MIX-AND-MATCH ALLOWED?
The government encourages the third dose to be the same as the first two, but doesn't mandate it.
HOW WELL DOES A THIRD DOSE WORK?
It helps at least some people. Canadian researchers this week reported 55% of transplant recipients given a third dose two months after standard vaccination had good antibody levels compared to 18% who were given a dummy third shot for comparison. Health experts urged these high-risk patients to continue masking and taking other precautions since there's no guarantee a third dose will work.
WHAT IF A THIRD DOSE STILL DOESN’T WORK?
It’s not a substitute for vaccination, but the FDA has authorized an antibody treatment as a preventive treatment if high-risk patients are exposed to the virus. And it's critical for family members and others close to fragile patients to be vaccinated.
More research is underway to better tease out whether some immune-compromised patients need still other options, such as carefully monitored changes to their medications.
WHAT IF I HAD THE SINGLE-DOSE JOHNSON & JOHNSON VACCINE?
There’s little data on how another dose works in high-risk people who received that vaccine, although it's likely a small number since fewer than 14 million Americans overall have received the J&J shot. Still, CDC counts at least 90,000 who have gotten another dose on their own.
FDA vaccines chief Dr. Peter Marks said the agency is working to get more information about immune-suppressed J&J patients but that for now, the evidence only backs a recommendation of extra doses for Pfizer and Moderna recipients with fragile immune systems.
IS THIS A BOOSTER?
Not really, because boosters are for people whose immunity wanes over time and these high-risk groups didn’t get enough protection to begin with. They now will qualify for a third dose at least 28 days after their second shot — making a third dose part of their initial prescription. That’s similar to how France has handled vaccinations for the immune-compromised since April.
WHAT ABOUT BOOSTER SHOTS FOR EVERYONE ELSE?
U.S. health authorities insist it’s not yet time for booster doses for the general population.
“We believe sooner or later you will need a booster for durability of protection” -- but not yet, Dr. Anthony Fauci, the government’s top infectious diseases expert, told reporters this week.
The CDC is closely monitoring rates of COVID-19 hospitalizations and deaths, as well as long-running studies of how often vaccinated health workers experience breakthrough infections, especially with the extra-contagious delta variant. That evidence will drive any decision.